Key points from article :
Capstan Medical, a California-based company specializing in robotic-enabled tools for heart valve repair, has raised $110 million in an oversubscribed Series C funding round led by Eclipse. Existing investors, including Intuitive Ventures and Yu Galaxy, alongside new backers like Gideon Strategic Partners, contributed to the round.
Capstan Medical focuses on surgical robotics paired with catheter-based technology and implants to repair and replace heart valves. The funds will be used to expand the company's reach within healthcare. CEO Maggie Nixon emphasized the transformative potential of robotic-assisted, minimally invasive heart valve repair, which could significantly improve care for millions suffering from heart valve disease. She highlighted the importance of innovation in addressing the urgent needs of an underserved patient population.
The funding builds on Capstan's prior success, including a $31.4 million Series B round in 2023, also led by Eclipse. Heart disease remains the leading cause of death in the U.S., with a striking lack of public awareness about its prevalence. The American Heart Association reports that over half of surveyed adults in a 2023 poll were unaware of the extent of heart disease's impact.
Capstan joins other innovators in cardiovascular health, such as Story Health, which integrates AI, telehealth, and health coaching, and Eko Health, whose FDA-cleared AI tool aids in early detection of heart failure indicators. Other notable players include CardioSignal, CardioOne, and Moray Medical, each contributing unique technologies to address heart disease.
By advancing robotic platforms for heart valve interventions, Capstan Medical aims to make life-saving care more accessible and effective.
